• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Darrell Baker - Articles and news items

GlaxoSmithKline logo

Anoro® Ellipta® (umeclidinium/vilanterol) gains approval in Japan for the treatment of COPD

Industry news / 4 July 2014 / GlaxoSmithKline

GlaxoSmithKline plc and Theravance, Inc. announced that the Japanese Ministry of Health, Labour and Welfare has approved Anoro® Ellipta® (umeclidinium/vilanterol) for the relief of various symptoms due to airway obstruction with chronic obstructive pulmonary diseases…

GlaxoSmithKline logo

GSK and Theravance announce positive data from two studies evaluating the efficacy and safety of Incruse™ Ellipta® when added to Relvar®/Breo® Ellipta® in patients with COPD

Industry news / 11 June 2014 / GlaxoSmithKline

GlaxoSmithKline plc and Theravance, Inc. announced positive results from two phase III studies, which showed that patients with chronic obstructive pulmonary disease who received the anticholinergic, Incruse™ Ellipta®…

GlaxoSmithKline logo

GSK presents positive data at ATS 2014 from study evaluating efficacy and safety of Incruse™ Ellipta® added to Advair® Diskus® in patients with COPD

Industry news / 20 May 2014 / GlaxoSmithKline

GlaxoSmithKline plc presented data at the American Thoracic Society (ATS) from a late-stage clinical study…

GlaxoSmithKline logo

GSK receives EU marketing authorisation for Incruse (umeclidinium) for the treatment of COPD

Industry news / 29 April 2014 / GlaxoSmithKline

GlaxoSmithKline plc announced that the European Commission has granted marketing authorisation for Incruse® (umeclidinium)…

GlaxoSmithKline logo

GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS® and ADVAIR® DISKUS®

Industry news / 14 March 2014 / GlaxoSmithKline

GlaxoSmithKline plc and Theravance, Inc. announced positive results from three phase III studies…

GlaxoSmithKline logo

Patient recruitment completes in landmark RELVAR®/ BREO® ELLIPTA® study to understand mortality and morbidITy (SUMMIT) in COPD

Industry news / 14 March 2014 / GlaxoSmithKline

GlaxoSmithKline plc and Theravance, Inc. announced that recruitment of patients into the “Study to Understand Mortality and MorbidITy”, known as SUMMIT, has completed enrolment…

GlaxoSmithKline logo

RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD

Industry news / 18 November 2013 / GlaxoSmithKline

RELVAR® ELLIPTA® is now licensed across 31 European countries…

GlaxoSmithKline logo

BREO™ ELLIPTA™ gains US approval for the treatment of COPD

Industry news, News / 10 May 2013 / GlaxoSmithKline

GlaxoSmithKline and Theravance announced that the US FDA has approved BREO™ ELLIPTA™…

GlaxoSmithKline logo
GlaxoSmithKline logo

GSK and Theravance announce initial outcomes from pivotal Phase III studies

Industry news, News / 9 January 2012 / GlaxoSmithKline

GSK and Theravance, Inc. announced the completion of the phase III registration programme…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +